Shariaportfolio Inc. Invests $1.15 Million in Novo Nordisk A/S $NVO

Shariaportfolio Inc. bought a new stake in Novo Nordisk A/S (NYSE:NVO) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 31,191 shares of the company’s stock, valued at approximately $1,146,000. Novo Nordisk A/S comprises 0.5% of Shariaportfolio Inc.’s investment portfolio, making the stock its 25th largest position.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Godfrey Financial Associates Inc. acquired a new position in Novo Nordisk A/S during the fourth quarter worth approximately $25,000. Scarborough Advisors LLC acquired a new stake in shares of Novo Nordisk A/S in the first quarter valued at approximately $26,000. WealthCollab LLC lifted its position in shares of Novo Nordisk A/S by 93.5% in the fourth quarter. WealthCollab LLC now owns 538 shares of the company’s stock valued at $27,000 after buying an additional 260 shares during the last quarter. American National Bank & Trust bought a new position in shares of Novo Nordisk A/S during the 4th quarter worth approximately $28,000. Finally, Maseco LLP bought a new position in shares of Novo Nordisk A/S during the 4th quarter worth approximately $29,000. Institutional investors own 11.54% of the company’s stock.

Analyst Ratings Changes

NVO has been the topic of a number of research analyst reports. Citigroup restated a “neutral” rating on shares of Novo Nordisk A/S in a research note on Monday, July 20th. Nordea Equity Research raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Friday, June 19th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Novo Nordisk A/S in a report on Monday, July 20th. HSBC reissued a “hold” rating on shares of Novo Nordisk A/S in a research report on Monday, July 6th. Finally, Zacks Research cut shares of Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a research note on Monday, July 13th. Five equities research analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, Novo Nordisk A/S presently has a consensus rating of “Hold” and an average target price of $65.56.

Trending Headlines about Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo Nordisk’s existing obesity business remains a key support. The company recently received European approval for a once-daily Wegovy pill and partnered with Crux to expand access to Wegovy through U.S. employer health plans, potentially broadening distribution and affordability. Novo Nordisk Teams Up With Crux To Expand Wegovy Access
• Neutral Sentiment: Some investor commentary indicates that Novo Nordisk’s current revenue drivers, particularly its GLP-1 medicines, remain intact despite the pipeline setback. However, the failed trial increases reliance on those products for future growth. NVO Stock Slumps After Late-Stage Trial Fails Primary Goal
• Negative Sentiment: In the Phase 3 ZEUS trial, ziltivekimab failed to significantly reduce major adverse cardiovascular events versus placebo in patients with cardiovascular disease, chronic kidney disease and inflammation. The result eliminates or reduces the near-term commercial potential of a drug intended to expand Novo Nordisk’s cardiovascular portfolio. Novo Nordisk’s Inflammation Drug Fails to Reduce Cardiovascular Risk in Trial
• Negative Sentiment: The setback is weighing on investor confidence in Novo Nordisk’s pipeline and has pushed the stock lower as markets reassess future growth and valuation. Novo Nordisk Shares Dive After Heart Medicine Fails Trial
• Negative Sentiment: Erste Group Bank also trimmed its fiscal 2026 earnings estimate to $3.20 per share from $3.22, below the $3.39 consensus estimate, adding to the cautious outlook. Novo Nordisk Analyst Estimate Update

Novo Nordisk A/S Stock Performance

NYSE:NVO opened at $47.20 on Monday. The stock has a 50 day simple moving average of $46.92 and a 200 day simple moving average of $45.40. The stock has a market cap of $210.74 billion, a P/E ratio of 11.08, a PEG ratio of 4.30 and a beta of 0.77. Novo Nordisk A/S has a 1-year low of $35.12 and a 1-year high of $64.16. The company has a current ratio of 0.79, a quick ratio of 0.56 and a debt-to-equity ratio of 0.59.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings data on Tuesday, March 31st. The company reported $1.03 EPS for the quarter. The firm had revenue of $10.85 billion for the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%. Research analysts anticipate that Novo Nordisk A/S will post 3.38 earnings per share for the current year.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.